reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 14 Sponsors

Mar 10, 2026 · Office of the Governor

Signed by the Governor on 2026-03-10 H.J. 547

Mar 5, 2026 · Senate

Delivered to the Governor on 2026-03-05 H.J. 520

Mar 4, 2026 · Senate

Signed by the President S.J. 470

Mar 3, 2026 · Senate

Signed by the Speaker H.J. 492

Mar 2, 2026 · Senate

Senate Do Pass , Passed, YEAS 21, NAYS 12 S.J. 429

Feb 26, 2026 · Senate

Remove from Consent Calendar S.J. 412

Feb 25, 2026 · Senate

Scheduled for hearing S.J. 1

Feb 25, 2026 · Senate

Health and Human Services Do Pass , Passed, YEAS 6, NAYS 0 S.J. 21

Feb 25, 2026 · Senate

Certified uncontested, placed on consent , Passed, S.J. 21

Feb 10, 2026 · Senate

First read in Senate and referred to Senate Health and Human Services S.J. 232

Feb 9, 2026 · House

House of Representatives Do Pass , Passed, YEAS 58, NAYS 7 H.J. 265

Feb 5, 2026 · House

Scheduled for hearing H.J. 1

Feb 5, 2026 · House

Health and Human Services Do Pass , Passed, YEAS 13, NAYS 0 H.J. 13

Jan 21, 2026 · House

First read in House and referred to House Health and Human Services H.J. 104